AR242832A1 - Polidomas productores de anticuerpos monoclonales hibridos biespecificos contra la fibrina y uk y/o pro uk y metodo para producirlos. - Google Patents

Polidomas productores de anticuerpos monoclonales hibridos biespecificos contra la fibrina y uk y/o pro uk y metodo para producirlos.

Info

Publication number
AR242832A1
AR242832A1 AR89314993A AR31499389A AR242832A1 AR 242832 A1 AR242832 A1 AR 242832A1 AR 89314993 A AR89314993 A AR 89314993A AR 31499389 A AR31499389 A AR 31499389A AR 242832 A1 AR242832 A1 AR 242832A1
Authority
AR
Argentina
Prior art keywords
polydomes
monoclone
pro
producing
bodies against
Prior art date
Application number
AR89314993A
Other languages
English (en)
Original Assignee
Takeda Chemical Industries Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Takeda Chemical Industries Ltd filed Critical Takeda Chemical Industries Ltd
Application granted granted Critical
Publication of AR242832A1 publication Critical patent/AR242832A1/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/46—Hybrid immunoglobulins
    • C07K16/468—Immunoglobulins having two or more different antigen binding sites, e.g. multifunctional antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/68—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment
    • A61K47/6801—Drug-antibody or immunoglobulin conjugates defined by the pharmacologically or therapeutically active agent
    • A61K47/6803—Drugs conjugated to an antibody or immunoglobulin, e.g. cisplatin-antibody conjugates
    • A61K47/6811—Drugs conjugated to an antibody or immunoglobulin, e.g. cisplatin-antibody conjugates the drug being a protein or peptide, e.g. transferrin or bleomycin
    • A61K47/6815—Enzymes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/68—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment
    • A61K47/6835—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment the modifying agent being an antibody or an immunoglobulin bearing at least one antigen-binding site
    • A61K47/6875—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment the modifying agent being an antibody or an immunoglobulin bearing at least one antigen-binding site the antibody being a hybrid immunoglobulin
    • A61K47/6879—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment the modifying agent being an antibody or an immunoglobulin bearing at least one antigen-binding site the antibody being a hybrid immunoglobulin the immunoglobulin having two or more different antigen-binding sites, e.g. bispecific or multispecific immunoglobulin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
AR89314993A 1988-09-27 1989-09-25 Polidomas productores de anticuerpos monoclonales hibridos biespecificos contra la fibrina y uk y/o pro uk y metodo para producirlos. AR242832A1 (es)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
JP24354488 1988-09-27
JP30192588 1988-11-28
JP6294089 1989-03-14
JP16487389 1989-06-27
JP20893689A JP3177776B2 (ja) 1988-09-27 1989-08-11 ハイブリッドモノクローナル抗体，抗体産生ポリドーマおよび抗体含有薬剤

Publications (1)

Publication Number Publication Date
AR242832A1 true AR242832A1 (es) 1993-05-31

Family

ID=27523741

Family Applications (1)

Application Number Title Priority Date Filing Date
AR89314993A AR242832A1 (es) 1988-09-27 1989-09-25 Polidomas productores de anticuerpos monoclonales hibridos biespecificos contra la fibrina y uk y/o pro uk y metodo para producirlos.

Country Status (15)

Country Link
US (1) US5506135A (es)
EP (1) EP0363712B1 (es)
JP (1) JP3177776B2 (es)
KR (1) KR900004351A (es)
CN (1) CN1041783A (es)
AR (1) AR242832A1 (es)
AT (1) ATE140930T1 (es)
AU (1) AU628857B2 (es)
DE (1) DE68926899T2 (es)
DK (1) DK474189A (es)
FI (1) FI894551A (es)
HU (1) HUT55445A (es)
IL (1) IL91649A (es)
NO (1) NO893818L (es)
PT (1) PT91808B (es)

Families Citing this family (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20030068322A1 (en) * 1988-04-18 2003-04-10 Immunomedics, Inc. Methods of antibody-directed enzyme-prodrug therapy
TW212184B (es) * 1990-04-02 1993-09-01 Takeda Pharm Industry Co Ltd
JPH0576385A (ja) * 1990-12-18 1993-03-30 Takeda Chem Ind Ltd キメラ抗体およびその用途
AP257A (en) * 1991-04-26 1993-06-03 Surface Active Ltd A method of releasing an antigen from an antibody and methods for their use in diagnosis and therapy.
WO2015053381A1 (ja) * 2013-10-10 2015-04-16 幸成 加藤 抗ポドプラニン抗体
SG11201910113PA (en) * 2017-05-02 2019-11-28 Nat Cancer Center Japan Plasmin-cleavable anti-insoluble fibrin antibody-drug conjugate

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4474893A (en) * 1981-07-01 1984-10-02 The University of Texas System Cancer Center Recombinant monoclonal antibodies
US4714681A (en) * 1981-07-01 1987-12-22 The Board Of Reagents, The University Of Texas System Cancer Center Quadroma cells and trioma cells and methods for the production of same
ES8504461A1 (es) * 1982-04-12 1985-04-16 Hybritech Inc Un procedimiento para obtener un polidoma.
US4916070A (en) * 1986-04-14 1990-04-10 The General Hospital Corporation Fibrin-specific antibodies and method of screening for the antibodies
EP0241907A3 (en) * 1986-04-14 1989-09-13 The General Hospital Corporation Heterobifunctional antibodies and method of use

Also Published As

Publication number Publication date
DK474189A (da) 1990-03-28
NO893818L (no) 1990-03-28
IL91649A0 (en) 1990-04-29
KR900004351A (ko) 1990-04-12
US5506135A (en) 1996-04-09
FI894551A0 (fi) 1989-09-26
DE68926899T2 (de) 1997-01-02
DE68926899D1 (de) 1996-09-05
NO893818D0 (no) 1989-09-26
PT91808A (pt) 1990-03-30
FI894551A (fi) 1990-03-28
IL91649A (en) 1994-10-21
HUT55445A (en) 1991-05-28
DK474189D0 (da) 1989-09-26
AU4174789A (en) 1990-04-05
ATE140930T1 (de) 1996-08-15
EP0363712A3 (en) 1990-08-16
EP0363712A2 (en) 1990-04-18
AU628857B2 (en) 1992-09-24
JP3177776B2 (ja) 2001-06-18
JPH03103175A (ja) 1991-04-30
PT91808B (pt) 1995-05-31
EP0363712B1 (en) 1996-07-31
CN1041783A (zh) 1990-05-02

Similar Documents

Publication Publication Date Title
GR3003648T3 (en) Method for producing composite cheeses.
TR27174A (tr) Vinilasetatin üretilmesine mahsus usul.
HK147494A (en) Method for producing at least two.layered articles
EP0657753A3 (en) Process for the production of microstructures.
ZA925771B (en) Method and apparatus for manufacturing mineral wool, and mineral wool produced thereby.
EP0594994A3 (en) Diamond semiconductor and manufacturing method.
EP0761683A4 (en) PROTEIN OR POLYPEPTIDE, PROCESS AND INTERMEDIATES FOR THEIR PREPARATION
ZA967258B (en) Method for the production of synthetic rutile.
AU6039590A (en) Laminated tile product, method for producing the same and method for installing the same
EP0602922A3 (en) Process for the preparation of silanes substituted with the dicyloalkyl group.
EP0612812A3 (en) Resin composites and method for producing the same.
EP0637060A3 (en) Process for the production of isolated intra-polycrystalline silicon structures.
GB2216211B (en) Insulated pipe joints and methods for forming them.
EP0602442A3 (de) Verfahren zur Herstellung von höheren, vorwiegend unverzweigten, primären Alkoholen.
EP0614974A3 (en) Bone - associated transcription control factor-like protein and process for producing the same.
EP0603865A3 (en) Process for the production of alanines.
AR242832A1 (es) Polidomas productores de anticuerpos monoclonales hibridos biespecificos contra la fibrina y uk y/o pro uk y metodo para producirlos.
EP0657438A3 (en) Process for the preparation of alkylulfinylbenzamides and 1,2-benzoisothiazol-3-ones.
TR27866A (tr) Alken polimerleri üretmeye mahsus yöntem.
ZA966474B (en) Method for preparing mineral pigments, the thus obtained mineral pigments and installation for implementing such method.
EP0599142A3 (de) Verfahren zur Herstellung von Immunkonjugaten.
EP0622450A3 (en) Detergent compositions and methods for their manufacture.
KR950700390A (ko) 강화 탄화수소, 그 제조방법 및 사용방법(fortified hydrocarbon and process for making and using the same)
EP0607005A3 (en) Isolated DNA encoding the Not I restriction endonuclease and process for its preparation.
GR3017286T3 (en) Mineral fine-pulverising method, and pulveriser for carrying out this method.